Fabio Trastulli

Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from Southern Italy cancer centers

Marco Picardi, Annamaria Vincenzi, Claudia Giordano, Novella Pugliese et autres

Studies in female Hodgkin lymphoma (HL) survivors have shown that doxorubicin hydrochloride exposure at young adult and adult (YA&A) age is associated with an increased risk of breast cancer (BC) regardless of chest-radiotherapy (c-RT). Although non-pegylated liposomal doxorubicin (NPLD)-based regimens have shown …

it (code pays fourni par la source)

Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from southern Italy cancer centers

Marco Picardi, Annamaria Vincenzi, Claudia Giordano, Novella Pugliese et autres

it, gb (code pays fourni par la source)

Lipegfilgrastim for primary prophylaxis of febrile neutropenia in patients treated for advanced-stage classical hodgkin lymphoma: successful outcomes from a multicenter cohort study

Claudia Giordano, M. Picardi, Fabiana Esposito, A. Vincenzi et autres

In patients with classical Hodgkin lymphoma (c-HL) undergoing ABVD chemotherapy for advanced disease, the optimal strategy to prevent febrile neutropenia (FN)—defined as fever ≥ 38 °C with absolute neutrophil count (ANC) < 1000/mm³—remains debated. Possible prophylaxis approaches include: i) secondary prophylaxis with …

it (code pays fourni par la source)

Real-life management of 476 older adults with Philadelphianegative acute lymphoblastic leukemia: a Campus ALL study

Marco Cerrano, Davide Lazzarotto, Eleonora Boscaro, Erika Borlenghi et autres

Not available.

it, us (code pays fourni par la source)

Lipegfilgrastim for primary prophylaxis of febrile neutropenia in patients treated for advanced-stage classical Hodgkin lymphoma: successful outcomes from a multicenter cohort study

Claudia Giordano, Marco Picardi, Fabiana Esposito, Annamaria Vincenzi et autres

it (code pays fourni par la source)

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers

Marco Picardi, Annamaria Vincenzi, Claudia Giordano, Novella Pugliese et autres

BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non-trial settings. We conducted a …

it, cz (code pays fourni par la source)

Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study

Roberta Della Pepa, Salvatore Palmieri, Stefano Rocco, Novella Pugliese et autres

Daratumumab combined with bortezomib, thalidomide, and dexamethasone (Dara-VTD) is a highly effective induction therapy for newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplantation (ASCT). However, its impact on stem cell mobilization requires a critical evaluation. This study examines …

it (code pays fourni par la source)

Long-acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine-treated patients with indolent B cell non-Hodgkin lymphoma: a multicentric real-life experience

Claudia Giordano, Marco Picardi, Annamaria Vincenzi, Alfonso Scarpa et autres

Febrile neutropenia (FN) is one of the most important clinical signs of infection, especially for older patients with indolent B cell non-Hodgkin lymphomas (iBC-NHLs) receiving frontline immune-chemotherapy with bendamustine-rituximab (BR). Data on the optimal strategy for infection prophylaxis from the start of …

it (code pays fourni par la source)

Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes

Sara Pepe, Candida Vitale, Diana Giannarelli, Andrea Visentin et autres

This study aimed to define the incidence and risk factors for diffuse large B cell lymphoma variant of RT (DLBCL-RT) in 976 patients with CLL who received ibrutinib therapy. DLBCL-RT was recorded in 83 (8.5%) patients, with a 7-year 15.6% rate. Most …

it, ch (code pays fourni par la source)

360 | BENDAMUSTINE SUPERCHARGE PLUS BRENTUXIMAB VEDOTIN AS EARLY SALVAGE FOLLOWING FAILURE OF 2 ABVD CYCLES IN HL: LONG‐TERM RESULTS OF A RETROSPECTIVE MULTICENTER STUDY

Claudia Giordano, Marco Picardi, Nicola Pugliese, Auri Marcelo Rizzo Vincenzi et autres

Treatment intensification with salvage therapy, and high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) is the best course of action for patients aged ≤ 60 years with classic Hodgkin lymphoma (c-HL) who fail to obtain complete metabolic remission (CMR) to first-line …

it (code pays fourni par la source)

Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin–bleomycin–vinblastine–dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long‐term efficacy results of a retrospective multicentre study

Claudia Giordano, Marco Picardi, Novella Pugliese, Annamaria Vincenzi et autres

it (code pays fourni par la source)

Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study

Sonia Morè, Irene Federici, Alessandra Bossi, Serena Rupoli et autres

Gaucher disease (GD) represents a lysosomal storage disease caused by a genetic defect of the enzyme β‐glucocerebrosidase (GBA) involved in the breakdown of complex glycosphingolipids, which are important components of cell membranes.

it (code pays fourni par la source)